Abstract
Forty patients with multiple recurrent superficial bladder tumours received an 8-week course of weekly instillations of 4' epirubicin 30 mg in 50 ml saline. The overall response rate was 58% and side effects were minimal.
Publication types
-
Clinical Trial
-
Multicenter Study
MeSH terms
-
Administration, Intravesical
-
Adult
-
Aged
-
Aged, 80 and over
-
Carcinoma, Transitional Cell / drug therapy*
-
Carcinoma, Transitional Cell / pathology
-
Epirubicin / administration & dosage
-
Epirubicin / adverse effects
-
Epirubicin / therapeutic use*
-
Female
-
Humans
-
Male
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy
-
Neoplasm Recurrence, Local / pathology
-
Neoplasm Staging
-
Prognosis
-
Urinary Bladder Neoplasms / drug therapy*
-
Urinary Bladder Neoplasms / pathology